The role of beta-blockers in the management of hypertension: An Asian perspective
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Tomlinson, B. | - |
dc.contributor.author | Dalal, J. J. | - |
dc.contributor.author | Huang, J. | - |
dc.contributor.author | Low, L. P. | - |
dc.contributor.author | Park, C. G. | - |
dc.contributor.author | Rahman, A. R. | - |
dc.contributor.author | Reyes, E. B. | - |
dc.contributor.author | Soenarta, A. A. | - |
dc.contributor.author | Heagerty, A. | - |
dc.contributor.author | Follath, F. | - |
dc.date.accessioned | 2021-09-07T12:39:10Z | - |
dc.date.available | 2021-09-07T12:39:10Z | - |
dc.date.created | 2021-06-14 | - |
dc.date.issued | 2011-05 | - |
dc.identifier.issn | 0300-7995 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/112496 | - |
dc.description.abstract | Following publication of the National Institute of Clinical Excellence (NICE) Guidelines in 2006, the use of beta beta-blockers as first-line therapy in hypertension has been somewhat controversial. However, a recent reappraisal of the European Society of Hypertension guidelines highlights that these agents exhibit similar BP lowering efficacy to other classes of agents, prompting a re-examination of the utility of these agents in various patient populations. The authors felt that it is important to address this controversy and provide an Asian perspective on the place of beta beta-blockers in current clinical practice and the benefits of beta beta-blockade in selected patient populations. In addition to their use as a potential first-line therapy in uncomplicated hypertension, beta beta-blockers have a particular role in patients with hypertension and comorbidities such as heart failure or coronary artery disease, including those who had a myocardial infarction. One advantage which beta beta-blockers offer is the additional protective effects in patients with prior cardiovascular events. Some of the disadvantages attributed to beta beta-blockers appear more related to the older drugs in this class and further appraisal of the efficacy and safety profile of newer beta beta-blockers will lend support to the current guideline recommendations in Asian countries and encourage increased appropriate use of beta beta-blockade in current clinical practice within Asia. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | TAYLOR & FRANCIS LTD | - |
dc.subject | ISCHEMIC BURDEN BISOPROLOL | - |
dc.subject | CORONARY-ARTERY-DISEASE | - |
dc.subject | BLOOD-PRESSURE | - |
dc.subject | HEART-RATE | - |
dc.subject | RANDOMIZED-TRIAL | - |
dc.subject | LONG-TERM | - |
dc.subject | CARDIOVASCULAR MORBIDITY | - |
dc.subject | ANTIHYPERTENSIVE DRUGS | - |
dc.subject | CYTOCHROME-P450 2D6 | - |
dc.subject | CALCIUM-ANTAGONIST | - |
dc.title | The role of beta-blockers in the management of hypertension: An Asian perspective | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, C. G. | - |
dc.identifier.doi | 10.1185/03007995.2011.562884 | - |
dc.identifier.scopusid | 2-s2.0-79954506127 | - |
dc.identifier.wosid | 000289528000015 | - |
dc.identifier.bibliographicCitation | CURRENT MEDICAL RESEARCH AND OPINION, v.27, no.5, pp.1021 - 1033 | - |
dc.relation.isPartOf | CURRENT MEDICAL RESEARCH AND OPINION | - |
dc.citation.title | CURRENT MEDICAL RESEARCH AND OPINION | - |
dc.citation.volume | 27 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 1021 | - |
dc.citation.endPage | 1033 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.subject.keywordPlus | ISCHEMIC BURDEN BISOPROLOL | - |
dc.subject.keywordPlus | CORONARY-ARTERY-DISEASE | - |
dc.subject.keywordPlus | BLOOD-PRESSURE | - |
dc.subject.keywordPlus | HEART-RATE | - |
dc.subject.keywordPlus | RANDOMIZED-TRIAL | - |
dc.subject.keywordPlus | LONG-TERM | - |
dc.subject.keywordPlus | CARDIOVASCULAR MORBIDITY | - |
dc.subject.keywordPlus | ANTIHYPERTENSIVE DRUGS | - |
dc.subject.keywordPlus | CYTOCHROME-P450 2D6 | - |
dc.subject.keywordPlus | CALCIUM-ANTAGONIST | - |
dc.subject.keywordAuthor | Adrenergic beta-antagonists | - |
dc.subject.keywordAuthor | Asia | - |
dc.subject.keywordAuthor | Guidelines | - |
dc.subject.keywordAuthor | Hypertension | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.